Clinical trials: Glucagon
Diabetes Mellitus Type 2
The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion
Glucagon like peptide 1 is produced in enteroendocrine L cells in the small intestine stimulated by peroral food intake. GLP-1 induces insulin secretion, and analogues are used in the treatment of DM2 (type 2 diabetes mellitus).
- Trial name
- NCT02796950
- Testing
- Acipimox
- Where
- Denmark
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Type I Diabetes Mellitus
Glutamine and Insulin Sensitivity in Type I Diabetes
Insulin is crucial to help the body metabolize ('burn') sugar (glucose). Even though juvenile (type 1) diabetes (T1D) is primarily due to the lack of insulin, patients with T1D tend to become less sensitive to insulin…
- Trial name
- NCT01467063
- Testing
- Glutamine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Nemours Children's Clinic
Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
A diagnosis of gestational diabetes mellitus (GDM)has significant implications for the future health of the mother. GDM is often the culmination of years of unrecognized and unmodified diabetes risk factors that lead to overt and…
- Conditions
- Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance
- Trial name
- NCT01234649
- Testing
- Metformin XR plus liraglutide
- Where
- United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Woman's
Type II Diabetes Mellitus
SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2
In Protocol 2, the investigators will determine the role of pancreatic hormones (increase in plasma glucagon and decrease in plasma insulin concentration) in the stimulation of EGP following SGLT2 inhibition.
- Trial name
- NCT02592421
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Obesity
High Quality Protein for Assisting With Weight Loss
The purpose of this study is to determine if, in presence of a reduced calorie diet, a breakfast containing high quality protein source (eggs) would be more effective in reducing hunger and increasing feeling of fullness compared…
- Trial name
- Egg_breakfast (NCT03085511)
- Testing
- Egg breakfast (EB), Weight Loss Counseling, Weight Loss Diet
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Texas Tech University
Insulin Sensitivity
Effect of Physiologic Hyperglucogonemia on Adipocyte Metabolism
Purpose/Objectives: To investigate the effect of hyperglucagonemia on insulin action, particularly on adipose tissue. Research Design/Plan: Normal glucose tolerant subjects will be studied.
- Trial name
- Glucagon (NCT04300049)
- Testing
- Glucagon Infusion, Saline
- Where
- 2 sites in United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Hyperglycemia Drug Induced
Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)
REMD-477 (Volagidemab) is a human anti-glucagon receptor antibody. Its proposed mechanism of action in controlling hyperglycemia is by blocking glucagon receptor (GCGR) signaling.
- Trial name
- NCT04330625
- Testing
- REMD-477
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Duke University
Obesity & Overweight, Mobility Disability
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
The primary objective of this study is to assess the effect of enobosarm on total body weight
- Conditions
- Obesity & Overweight, Mobility Disability, HOMA-IR
- Trial name
- PLATEAU (NCT07446998)
- Testing
- Enobosarm, Semaglutide (Wegovy) weekly injection
- Where
- 13 sites in United States
- Volunteers
- 239 people
- Sponsor
- Veru Inc.
Type 1 Diabetes
The Effect of Endogenous GLP-1 on Glucagon Secretion in Type 1 Diabetes
Type 1 diabetes is a serious and burdensome disease that carries the risk of severe complications and premature death, partly due to low blood sugar, also called hypoglycaemia.
- Trial name
- EX-HYPO (NCT07373236)
- Testing
- exendin(9-39)amide, Saline (0.9% NaCl)
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Asger Lund, MD
Insulin Secretion
Incretin Action in Physiology and Diabetes
This project is designed to advance understanding of the incretin effect in health and disease. This system of gut-islet linkage is essential for normal glucose tolerance, impaired in T2DM, and amenable to therapeutic…
- Trial name
- NCT02550548
- Testing
- GIP infusion, GLP-1 infusion, Ex-9 infusion
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- David D'Alessio, M.D.
Hypoglycemia, Diabetes Mellitus, Type 1
The Late Effects of Ethanol Intake on the Glucose Response to Subcutaneous Glucagon in Type 1 Diabetes
Objective: Because many people with type 1 diabetes drink ethanol and because glucagon is used to treat mild hypoglycaemia, it is essential to determine whether ethanol will impair the effectiveness of glucagon to increase…
- Trial name
- ALCO1 (NCT02881060)
- Testing
- Alcohol
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Hvidovre University Hospital
Type 1 Diabetes Mellitus
Glucagon Counterregulation in Type 1 Diabetes
The purpose of this study is to find out whether the combination of insulin and pramlintide is better than insulin alone at helping the pancreas release glucagon in response to a low blood sugar episode.
- Trial name
- NCT03547427
- Testing
- Basal insulin alone, Basal pramlintide and reduced basal insulin, CGM
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Virginia
Coronary Disease, Shock, Cardiogenic
GLP-1 and Hyperoxia for Organ Protection in Heart Surgery
Patients undergoing open heart surgery are at risk of suffering damage to the heart, brain and kidneys. This study is designed as a 2-by-2 randomized clinical trial with the purpose of investigating the organ protective effects…
- Conditions
- Coronary Disease, Shock, Cardiogenic, Renal Failure, Stroke
- Trial name
- GLORIOUS (NCT02673931)
- Testing
- Byetta (Lilly, Exenatide), Conoxia (AGA, oxygen), 20% Human Albumin
- Where
- Denmark
- Volunteers
- 1,400 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.
To explore the mechanism of action of ranolazine as a potential treatment for type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01843127
- Testing
- Ranolazine, Exenatide
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Gilead Sciences
Diabetes Mellitus, Type 2
A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
This study is designed to examine the efficacy and safety of 2 dose levels of weekly subcutaneously injected albiglutide compared with placebo and an open label reference arm of daily subcutaneous injections of liraglutide, in…
- Trial name
- NCT01733758
- Testing
- Albiglutide 30 mg weekly, Albiglutide 50 mg weekly, Liraglutide 0.9 mg daily
- Where
- 74 sites in Japan
- Volunteers
- 494 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 1
GPR119 Agonist for Hypoglycemia in Type 1 Diabetes
The purpose of this study is to test if a specific research medication could increase the response to low blood glucose in people with type 1 diabetes.
- Trial name
- PHROG (NCT04432090)
- Testing
- Study Medication (MBX-2982), No medication for this group
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Overweight and Obesity
Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment
Obesity has become an important public health issue that leads to insulin resistance, diabetes, hypertension, dyslipidemia, and cardiovascular diseases.
- Trial name
- NCT06069622
- Testing
- 24-hour ambulatory blood pressure, Liberal salt diet
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
Type 2 Diabetes Mellitus, PreDiabetes
Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes Mellitus
This study is conducted to examine GLP-1, insulin resistance and insulin sensitivity portfolio in Malay, Chinese and Indian populations in Malaysia and to study the effect of DPPIV inhibitor in T2DM patients with different…
- Trial name
- GLP-1 (NCT03659461)
- Testing
- Sitagliptin
- Where
- Malaysia
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- National University of Malaysia
Diabetes Mellitus, Type 2
Genetics of Response to Canagliflozin
Five daily doses of canagliflozin (300 mg) will be administered to healthy volunteers. Pharmacodynamic responses to canagliflozin will be assessed both at 2 days and 6 days after administration of the first dose of canagliflozin.
- Trial name
- NCT02891954
- Testing
- Canagliflozin
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
GLP-1, Obesity &Amp; Overweight
Effect of a Dietary Supplement on Hormones Involved in Appetite Regulation in Overweight and Obese Adults
Obesity is a chronic condition linked to numerous health risks and affects more than one billion people worldwide. While pharmacological treatments such as incretin-based therapies are available, they may have side effects, are…
- Conditions
- GLP-1, Obesity &Amp; Overweight, Dietary Supplement
- Trial name
- NCT07240246
- Testing
- Intervention: Dietary Supplement with Plant Extracts
- Where
- Austria
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- FFoQSI - Austrian Competence Centre for Feed and Food Quality, Safety & Innovation